The University of Southampton
University of Southampton Institutional Repository

A trial like ALIC4E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness?

A trial like ALIC4E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness?
A trial like ALIC4E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness?
ALIC4E is the first publicly funded, multicountry, pragmatic study determining whether antivirals should be routinely prescribed for influenza-like illness in primary care. The trial aims to go beyond determining the average treatment effect in a population to determining effects in patients with combinations of participant characteristics (age, symptom duration, illness severity, and comorbidities). It is one of the first platform, response-adaptive, open trial designs implemented in primary care, and this article aims to provide an accessible description of key aspects of the study design. 1) The platform design allows the study to remain relevant to evolving circumstances, with the ability to add treatment arms. 2) Response adaptation allows the proportion of participants with key characteristics allocated to study arms to be altered during the course of the trial according to emerging outcome data, so that participants' information will be most useful, and increasing their chances of receiving the trial intervention that will be most effective for them. 3) Because the possibility of taking placebos influences participant expectations about their treatment, and determining effects of the interventions on patient help seeking and adherence behaviour in real-world care is critical to estimates of cost-effectiveness, ALIC4E is an open-label trial.
2312-0541
1-6
Butler, Christopher C.
8bf4cace-c34a-4b65-838f-29c2be91e434
Coenen, Samuel
3d0dc4e0-e5ba-4d66-ba92-15900ccc551e
Saville, Benjamin R.
9a50164f-c694-46ee-83b9-d7813500bc0f
Cook, Johanna
2eb21e4e-2058-49ce-99a2-262d438bf988
Velden, Alike van der
1877ef56-44fb-42c9-9251-e3c7d1badb8b
Homes, Jane
b280d13d-f561-4277-a290-4d778878f113
Jong, Menno de
f4d62bcc-c4d0-4d26-990c-915489dbf113
Little, Paul
1bf2d1f7-200c-47a5-ab16-fe5a8756a777
Goossesns, Herman
0cc3d93b-aed0-4cbd-b3c6-1a82235de8a0
Beutles, Philipe
c9f14cd4-7ec8-43cb-9153-bc3b63613bd3
Ieven, Greet
627c0bd0-9a26-483e-a215-6a7ff2346bd5
Francis, Nicholas
9b610883-605c-4fee-871d-defaa86ccf8e
Moons, Pieter
19084ba6-52f5-4180-8c73-737e8b029578
Bongard, Emily
498cda67-5b1a-4f3a-98f1-9c2b01c48410
Verheij, Theo
772e019f-486f-4a64-9260-bac6446a85d2
Butler, Christopher C.
8bf4cace-c34a-4b65-838f-29c2be91e434
Coenen, Samuel
3d0dc4e0-e5ba-4d66-ba92-15900ccc551e
Saville, Benjamin R.
9a50164f-c694-46ee-83b9-d7813500bc0f
Cook, Johanna
2eb21e4e-2058-49ce-99a2-262d438bf988
Velden, Alike van der
1877ef56-44fb-42c9-9251-e3c7d1badb8b
Homes, Jane
b280d13d-f561-4277-a290-4d778878f113
Jong, Menno de
f4d62bcc-c4d0-4d26-990c-915489dbf113
Little, Paul
1bf2d1f7-200c-47a5-ab16-fe5a8756a777
Goossesns, Herman
0cc3d93b-aed0-4cbd-b3c6-1a82235de8a0
Beutles, Philipe
c9f14cd4-7ec8-43cb-9153-bc3b63613bd3
Ieven, Greet
627c0bd0-9a26-483e-a215-6a7ff2346bd5
Francis, Nicholas
9b610883-605c-4fee-871d-defaa86ccf8e
Moons, Pieter
19084ba6-52f5-4180-8c73-737e8b029578
Bongard, Emily
498cda67-5b1a-4f3a-98f1-9c2b01c48410
Verheij, Theo
772e019f-486f-4a64-9260-bac6446a85d2

Butler, Christopher C., Coenen, Samuel, Saville, Benjamin R., Cook, Johanna, Velden, Alike van der, Homes, Jane, Jong, Menno de, Little, Paul, Goossesns, Herman, Beutles, Philipe, Ieven, Greet, Francis, Nicholas, Moons, Pieter, Bongard, Emily and Verheij, Theo (2018) A trial like ALIC4E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness? ERJ Open Research, 4 (2), 1-6, [00046]. (doi:10.1183/23120541.00046-2018).

Record type: Article

Abstract

ALIC4E is the first publicly funded, multicountry, pragmatic study determining whether antivirals should be routinely prescribed for influenza-like illness in primary care. The trial aims to go beyond determining the average treatment effect in a population to determining effects in patients with combinations of participant characteristics (age, symptom duration, illness severity, and comorbidities). It is one of the first platform, response-adaptive, open trial designs implemented in primary care, and this article aims to provide an accessible description of key aspects of the study design. 1) The platform design allows the study to remain relevant to evolving circumstances, with the ability to add treatment arms. 2) Response adaptation allows the proportion of participants with key characteristics allocated to study arms to be altered during the course of the trial according to emerging outcome data, so that participants' information will be most useful, and increasing their chances of receiving the trial intervention that will be most effective for them. 3) Because the possibility of taking placebos influences participant expectations about their treatment, and determining effects of the interventions on patient help seeking and adherence behaviour in real-world care is critical to estimates of cost-effectiveness, ALIC4E is an open-label trial.

Text
00046-2018.full - Version of Record
Available under License Creative Commons Attribution.
Download (441kB)

More information

Accepted/In Press date: 16 April 2018
Published date: 1 May 2018

Identifiers

Local EPrints ID: 435421
URI: http://eprints.soton.ac.uk/id/eprint/435421
ISSN: 2312-0541
PURE UUID: 2f1b3bfd-d59e-418d-bcfe-61da2b3c06fa
ORCID for Paul Little: ORCID iD orcid.org/0000-0003-3664-1873
ORCID for Nicholas Francis: ORCID iD orcid.org/0000-0001-8939-7312

Catalogue record

Date deposited: 06 Nov 2019 17:30
Last modified: 12 Jul 2024 02:05

Export record

Altmetrics

Contributors

Author: Christopher C. Butler
Author: Samuel Coenen
Author: Benjamin R. Saville
Author: Johanna Cook
Author: Alike van der Velden
Author: Jane Homes
Author: Menno de Jong
Author: Paul Little ORCID iD
Author: Herman Goossesns
Author: Philipe Beutles
Author: Greet Ieven
Author: Pieter Moons
Author: Emily Bongard
Author: Theo Verheij

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×